Isradipine in prediabetic hypertensive subjects

Diabetes Care

Volumn 21, Issue 12, 1998, Pages 2103-2110

  Byington, Robert P ^a   Furberg, Curt D ^a   Craven, Timothy E ^a   Pahor, Marco ^b   Sowers, James R ^c  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FELODIPINE; FOSINOPRIL; HEMOGLOBIN A1C; HYDROCHLOROTHIAZIDE; ISRADIPINE; NIFEDIPINE; SULFONYLUREA;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DRUG EFFECT; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE;

EID: 0031767977     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.21.12.2103     Document Type: Article

References (27)

1. Sowers JR, Epstein M: Diabetes mellitus and associated hypertension, vascular disease, and nephropathy Hypertension 26:869-879, 1995
2. Hein KD, King GL: Vascular abnormalities in diabetes mellitus, In Endocrinology of the Vasculature. Sowers JR, Ed. Tatowa, NJ, Humana Press, 1996, p. 135-144
3. Muniyappa R, Srinivas PR, Ram JL, Walsh MF, Sowers JR: Calcium and protein kinase C mediate high-glucose-induced inhibition of inducible nitric oxide syntase in vascular smooth muscle cells. Hypertension 31:289-295, 1998
4. Curb JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB, Black H, Camel G, Davis BR, Frost PH, Gonzalez N, Guthrie G, Oberman A, Rutan GH, Stamler J, for the Systolic Hypertension in the Elderly Program Cooperative Research Group: Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA 276:1886-1892, 1996
5. Estacio RO, Jeffers BW, Hiatt WR, Bigger- staff SL, Gifford N, Schrier RW: The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 338:645-652, 1998
6. Tatti P, Pahor M, Byington RP, Di Mauro P, Guarisco R, Strollo G, Strollo F: Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM, Diabetes Care 21:597-603, 1998
7. Borhani NO, Mercuri M, Borhani PA, Buckalew VM, Canossa-Terris M, Carr AA, Kappagoda T, Rocco MV, Schnaper HW, Sowers JR, Bond MG: Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). JAMA 276:785-791, 1996
8. Byington RP, Craven TE, Furberg CD, Pahor M: Isradipine, raised glycosylated haemoglobin, and risk of cardiovascular events, Lancet 350:1075-1076, 1997
9. Furberg CD, Byington RP, Borhani NO: Design feature: Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). Am J Med 86 (Suppl. 4A):37-39, 1989
10. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20:1183-1197, 1997
11. Nehal M, Venugopal P, Baquer NZ: Changes in the lipid composition of red blood cells in hyperglycemic rats. Biochem Int 22:243-248, 1990
12. Mason RP: Membrane interaction of calcium channel antagonists modulated by cholesterol: implications for drug activity. Biochem Pharmacol 45:2173-2183, 1993
13. Giugliano D, Tortella R, Cacciapuoti F, Gentile S, Verza M, Varricchio M: Impairment of insulin secretion in man by nifedipine. Eur J Clin Pharmacol 18:395-398, 1980
14. Charles S, Ketelslegers J-M, Buysschaert M, Lambert AW: Hyperglycaemic effect of nifedipine. Br Med J 283:19-20, 1981
15. Kjellström, Blychert E, Lindgärde F: Short- term effects of felodipine in hypertensive type II diabetic males on sulfonylurea treatment. J Int Med 236:51-56, 1994
16. Alderman MH, Cohen H, Roqué R, Madhavan S: Effect of long-acting and short-acting calcium antagonists on cardiovascular outcomes in hypertensive patients. Lancet 349:594-598, 1997
17. Alderman MH, Madhaven S, Cohen H: Calcium antagonists and cardiovascular events in patients with hypertension and diabetes. Lancet 351:216-217, 1998
18. Heckbert SR, Psaty BM, Kaplan RC, Smith NL, Lemaitre RN, Koepsell TD, Siscovick DS: ACE inhibitors and MI risk in diabetics with hypertension (Revised Abstract). Circulation 97:826, 1998
19. Pahor M, Guralnik JM, Corti C, Foley DJ, Carbonin PU, Havlik RJ: Long-term survival and use of antihypertensive medications in older persons. J Am Geriatr Soc 43:1191-1197, 1995
20. Pahor M, Furberg CD, Psaty BM: Treatment of hypertensive patients with diabetes. Lancet 351:689-690, 1998
21. Hamilton BP: Treatment of essential hyper- tension with PN 200-110 (isradipine). Am J Cardiol 159:141B-145B, 1987
22. Yasky J, Ferrario CM: Noctural hypotension and ACE inhibitors. J Hum Hypertens 7:299-304, 1993
23. Psaty BM, Heckbert SR, Koepsell TD, Siscovick DS, Raghunathan TE, Weiss NS, Rosendaal FR, Lemaitre RN, Smith NL, Wahl PW, Wagner EH, Furberg CD: The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 274:620-625, 1995
24. Furberg CD, Psaty BM, Meyers JV: Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation 92:1326-1331, 1995
25. 2+ antagonists inhibit DNA fragmentation and toxic cell death induced by acetaminophen. FASEB J 7:453-463, 1993
26. Connor J, Sawczuk IS, Benson MC, Tomashefsky P, O'Toole KM, Olsson CA, Buttyan R: Calcium channel antagonists delay regression of androgen dependent tis- sues and suppress gene activity associated with cell death. Prostate 13:119-130, 1988
27. Du KL, Sui GZ, Stocklauser-Färber K, Weiß J, Zink S, Schwippert B, Wu QX, Tschöpe D, Rösen P: Induction of apoptosis by high proinsulin and glucose in cultured human umbilical vein endothelial cells is mediated by reactive oxygen species. Diabetologia 41:249-256, 1998